Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication

J Virol Methods. 2010 Nov;169(2):380-4. doi: 10.1016/j.jviromet.2010.08.009. Epub 2010 Aug 14.

Abstract

Replication of infectious hepatitis C virus in Huh7 cells, a human hepatocyte cell line, has become possible due to the unique properties of the JFH1 isolate. Developing reporter virus systems for a simple titration has been attempted by integrating heterologous reporter genes into the JFH1 genome, resulting in a big infectivity reduction that limits the usefulness of such reporter systems. To overcome this problem, JFH1-infected Huh7 cells were cultured continuously for 2 years to obtain Huh7-adapted JFH1 variants capable of yielding up to 1000-fold higher titers. Sequence analysis of variant genome RNA suggested that this adapted population consisted mainly of two variants. By joining the 5'-half of the obtained representative viral complementary DNA (cDNA) fragments of the variants with the 3'-half of the wild-type's, two prototype clones, A/WT and B/WT, were constructed. Replication of A/WT and B/WT viruses in Huh7 cells showed up to 100-1000-fold higher titers than the wild-type. A Renilla luciferase cDNA was inserted into the Nonstructural Protein 5A region of the A/WT and B/WT cDNA to generate A/WT-Rluc and B/WT-Rluc, respectively. Transfection of Huh7 cells with in vitro-transcribed A/WT-Rluc and B/WT-Rluc RNA resulted in production of infectious viruses with approximately 15- and 25-fold higher titers, respectively, than the wild-type RNA. The replication of A/WT-Rluc and B/WT-Rluc viruses was more vigorous than the wild-type even with insertion of the luciferase cDNA showing a good correlation of luciferase activities with infectious titers. Furthermore, interferon-alpha inhibited the replication of A/WT-Rluc and B/WT-Rluc viruses in a dose-dependent manner as determined by a luciferase assay. These results imply that our system is potentially a tool useful for screening anti-hepatitis C virus drugs in a simple and time/cost-saving manner.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptation, Biological
  • Antiviral Agents / pharmacology*
  • Cell Line
  • Drug Evaluation, Preclinical / methods*
  • Genes, Reporter
  • Hepacivirus / drug effects*
  • Hepacivirus / physiology*
  • Hepatocytes / virology
  • Humans
  • Interferon-alpha / pharmacology
  • Luciferases, Renilla / genetics
  • Luciferases, Renilla / metabolism
  • Microbial Sensitivity Tests / methods
  • RNA, Viral / genetics
  • Sequence Analysis, DNA
  • Serial Passage
  • Staining and Labeling / methods
  • Virus Cultivation / methods
  • Virus Replication / drug effects*

Substances

  • Antiviral Agents
  • Interferon-alpha
  • RNA, Viral
  • Luciferases, Renilla